iQure Pharma’s iQ-007 Achieves Critical Pre-Clinical Milestone

Princeton, NJ, May 15, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has achieved a major milestone by completing their preclinical formulation development for iQ-007, a novel anticonvulsant compound.

In the last two months, the new formulation of its lead compound iQ-007 was tested in an extensive pharmacokinetic study after oral administration in male and female rats. The results show excellent bioavailability, clear dose linearity over a large dose range from 5-400 mg/kg, and most importantly, a tripling of the elimination half-life. No gender differences were observed and based on the subsequent population analysis, this new formulation will allow the required threshold concentration to be reached within 24 hours, with a three times daily administration. Assuming a doubling of half-life in humans, which is often seen in antiepileptic drugs, this would result in a twice daily administration in the clinic trial.

“This is very good news and allows us to complete the IND-enabling package and move to the clinic development phase as soon as possible.” said iQure Chief Operating Officer, Henk de Wilde.

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

iQure Pharma’s iQ-007 & iQ-008 Compounds Continue to Deliver Promising Results

Princeton, NJ, February 24, 2023 ─ iQure Pharma Inc. (iQure), a US-based biotech company, is making significant progress in the development of its two assets, iQ-007, a novel anticonvulsant and analgesic compound, and iQ-008, a novel compound against neuropathic pain.

In the last few months, its lead compound iQ-007, has completed a set of critical experiments with two important results: increasing iQ-007’s excellent safety profile by establishing the lack of abuse potential and lack of genotoxicity and confirming additional favorable characteristics of the compound. These include a positive brain uptake based on the MDCK-MDR1 Permeability Assay, plasma protein binding in a series of species, and solubility experiments. In collaboration with researchers from the Jagiellonian University, a series of formulation and pharmacokinetic experiments were conducted to optimize the iQ-007 formulation. This will allow completion of the formulation development for the next set of experiments to continue on schedule. Initial formulation work was also completed for iQ-008, enabling further pharmacokinetic and efficacy studies as part of the NIH PSPP program.

“This is very good news and an important step in the continued development of iQ-007 and iQ-008 as promising therapeutics,” said iQure Chief Operating Officer Henk de Wilde. “With the new formulations under development, we can achieve the full potential of both compounds and maximize the benefit for future patients.”

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

iQure Pharma Attending JPM Week in San Francisco — January 9-12, 2023

Princeton, NJ, December 14, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, is attending the 41st Annual J.P. Morgan Health Care Conference, JPM Week, in January 2023.

iQure’s portfolio of treatments in Epilepsy, Pain and other neurodegenerative diseases has had a number of positive developments in the last few months. As a result, iQure Pharma has intensified its focus in the areas of strategic partnering and fundraising. Pawel Zolnierczyk, CEO and Henk de Wilde, COO and R&D Director, will participate in JPM Week to further explore strategic collaborations with pharma and expand current fundraising activities.

“These are exciting times for iQure with very promising market traction and significant interest from pharma for both of our assets,” said iQure CEO Pawel Zolnierczyk. “We are currently in active discussions with large pharma and look forward to continuing these at JPM. While we are there, we will be meeting with VCs and CVCs to expand our fundraising efforts.”

For those interested in meeting with iQure Pharma in San Francisco during JPM Week, please register here:

iQure Pharma at 2023 JPM BIO Partnering

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.